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Abstract
In most developed countries, HCV is primarily transmitted by injecting drug users (IDUs). HCV antiviral treatment is effective,
and deemed cost-effective for those with no re-infection risk. However, few active IDUs are currently treated. Previous
modelling studies have shown antiviral treatment for active IDUs could reduce HCV prevalence, and there is emerging
interest in developing targeted IDU treatment programmes. However, the optimal timing and scale-up of treatment is
unknown, given the real-world constraints commonly existing for health programmes. We explore how the optimal
programme is affected by a variety of policy objectives, budget constraints, and prevalence settings. We develop a model of
HCV transmission and treatment amongst active IDUs, determine the optimal treatment programme strategy over 10 years
for two baseline chronic HCV prevalence scenarios (30% and 45%), a range of maximum annual budgets (»50,000–300,000
per 1,000 IDUs), and a variety of objectives: minimising health service costs and health utility losses; minimising prevalence
at 10 years; minimising health service costs and health utility losses with a final time prevalence target; minimising health
service costs with a final time prevalence target but neglecting health utility losses. The largest programme allowed for a
given budget is the programme which minimises both prevalence at 10 years, and HCV health utility loss and heath service
costs, with higher budgets resulting in greater cost-effectiveness (measured by cost per QALY gained compared to no
treatment). However, if the objective is to achieve a 20% relative prevalence reduction at 10 years, while minimising both
health service costs and losses in health utility, the optimal treatment strategy is an immediate expansion of coverage over
5–8 years, and is less cost-effective. By contrast, if the objective is only to minimise costs to the health service while attaining
the 20% prevalence reduction, the programme is deferred until the final years of the decade, and is the least cost-effective
of the scenarios.
Citation: Martin NK, Pitcher AB, Vickerman P, Vassall A, Hickman M (2011) Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention
amongst a Population of Injecting Drug Users. PLoS ONE 6(8): e22309. doi:10.1371/journal.pone.0022309
Editor: Pieter H. M. van Baal, Erasmus University Rotterdam, The Netherlands
Received September 10, 2010; Accepted June 24, 2011; Published August 11, 2011
Copyright:  2011 Martin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: NKM is supported by the Scottish Government Hepatitis C Action Plan and Centre for Research on Drugs and Health Behaviour NIHR Grant. ABP is
supported by the ‘DyXi’ project of the SYSCOMM programme of the French National Agency for Research (grant number ANR-08-SYSC-008). PV is supported by a
MRC New Investigator Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: natasha.martin@bristol.ac.uk (NKM); ashley.pitcher@balliol.oxon.org (ABP)
. These authors contributed equally to this work.
Introduction
Hepatitis C virus (HCV) is a comparatively common blood-
borne disease with 130–170 million people (2–3%) globally
infected [1]. It is one of the leading causes of chronic liver disease
worldwide, and is the fastest growing cause of liver transplantation
in developed countries [2]. If left untreated, about 7–18% progress
to liver disease within 20 years, which can result in liver failure,
cirrhosis, hepatocellular carcinoma, and death [3].
The primary mode of transmission in developed countries is
amongst active injecting drug users (IDUs) where it is easily
transmitted through needle and syringe sharing. In the UK, most
developed countries, and many other developing countries without
marked iatrogenic HCV risk (such as South Asia), over 80% of
new cases are attributed to injecting drugs, with 15–90% of IDUs
testing positive for HCV antibodies [4–7]. Public health
interventions such as health education and advice, needle and
syringe exchange, and opiate substitution therapy aim to prevent
transmission by reducing unsafe injecting [4]. However, despite
increases in intervention exposure, public health surveillance
indicates that substantial decreases in HCV prevalence have not
been achieved [8].
Antiviral treatment (peginterferon-alfa and ribavirin) for HCV
has been established as effective and results in viral clearance in
about 45–80% of cases, depending on genotype [9–11]. Economic
evaluations have found treatment cost-effective for a population
with no re-infection risk [12]. Since 2002, guidelines in the US and
UK do not exclude active IDUs from treatment eligibility, given
the growing evidence that IDUs exhibit a similar response to
treatment, and could be just as compliant with treatment as ex- or
non-IDUs [11–13]. Despite these recommendations and the high
proportion of IDUs infected, very few (v3–4%) active IDUs have
ever been treated [14,15]. Recent mathematical modelling has
predicted that antiviral treatment can be an effective prevention
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measure amongst IDUs, with modest and achievable levels of
treatment resulting in substantial reductions in infected prevalence
[16–19]. Hence, treatment of injectors could have substantial
benefits in relation to reducing ongoing transmission (despite some
of the difficulties in delivering the treatment and potential loss of
sustained viral response (SVR)).
Ideally, from an economic perspective, any intervention, such as
HCV treatment, that has been found to be cost-effective would be
fully funded immediately. In reality, however, funding and access
to treatment may not be provided as programmes are always faced
with a number of constraints. Globally, there are many
interventions that fall under the WHO willingness to pay
thresholds, but remain underfinanced by countries and face
substantial budget constraints. For example, in Australia free HCV
treatment is available under the national health care system, but
the government acknowledges a capacity limit within the specialist
hepatitis C treatment services which restricts the numbers that can
undergo treatment each year [20]. In the UK, NICE (National
Institute for Health and Clinical Excellence) issues guidelines on
which treatments should be offered, but different regions
frequently offer different levels of treatment. Global (and
sometimes national) institutions frequently respond to this issue
by setting targets, either for coverage or to achieve specific
reductions in prevalence. Indeed, the low coverage of HCV
treatment across the UK has resulted in the development of a
number of national action plans (Scotland, Wales, and England)
which aim to expand treatment coverage over the next 5 years
[20–22]. These action plans do not specifically target current
IDUs, despite the growing interest in targeting antiviral treatment
to IDUs as a means of prevention, and general movements for
more active IDUs to be treated [20,23]. This study examines how
constraints (annual maximum budgets) and objectives (prevalence
targets, desire to minimise health utility losses) are likely to
influence optimal timing and intensity of scale-up, and the
subsequent costs, impact, and cost per QALY (quality-adjusted
life year) gained in each scenario.
As such, our aim is not to perform an economic evaluation of
antiviral treatment, but to inform policy makers on how the
optimal treatment strategy and programme cost-effectiveness
(measured by cost per QALY gained) may be affected when
different constraints are applied. This type of analysis (using
optimal control theory to determine the optimal resource
allocation as an epidemic progresses) has been used before in
infectious disease prevention [24–27]. Hence, our aims and
mathematical techniques are well established in infectious disease
literature, although its specific application to HCV is novel.
Importantly, few have managed to present this technique to a
broader audience (outside of mathematical modellers) and with
real-world budget constraints and objectives.
We parameterise our epidemic model with recent data from the
UK, and our cost coefficients with current UK costs of antiviral
treatment and HCV infection. We then examine the optimal
treatment strategy for different economic and policy objectives,
which range from ‘ideal’ public health objectives (where health
service costs and HCV health utility loss or just prevalence is
minimised) to ‘less ideal’ but perhaps more realistic scenarios with
a specific policy objective of reducing prevalence by a specific
percentage by the end of the 10 year timeframe. The specific
scenarios we examine are: 1) minimising health service costs and
health utility (QALY) loss; 2) minimising prevalence; 3) minimising
health service costs and health utility loss while achieving a final
time prevalence reduction of 20%; 4) minimising health service
costs while achieving a final time prevalence reduction of 20%
(and neglecting health utility loss). This is done for a variety of
annual budget constraints and two baseline prevalences (30% and
45%).
Methods
Model background and assumptions
Infection with HCV leads to a relatively short (weeks to
months) acute stage, which may lead to a prolonged chronic stage
lasting for decades [28]. A fraction (about 26%) of acute
infections are spontaneously cleared by the individual [29]. Due
to the short duration of the acute stage, the number of infections
caused by people with acute HCV who spontaneously clear is
small, and we neglect it for model simplicity. Those who
spontaneously clear become susceptible again, and the remaining
fraction who do not spontaneously clear progress to the chronic
infection stage. There is controversy around the possibility of
sterilising immunity following exposure to HCV. However, given
that immunity following exposure to HCV is uncertain, and
previous models have shown that, if present, this population is
relatively small, we neglect it for the purposes of this model
[16,17].
Antiviral treatment leads to a substantial reduction in viral load
in the first few weeks (even among some eventual nonresponders)
[30]. Hence, we assume that active IDUs currently on treatment
are non-infectious. Due to the lack of definitive evidence to suggest
otherwise, we assume that the chances of spontaneous clearance
are equal for naı¨ve (those who have never been infected) and re-
infected IDUs. Furthermore, we assume that the probability of
treatment success is the same between naı¨ve and re-infecteds,
which is supported by experimental evidence [31]. Finally, we
assume that treatment failures return to the chronically infected
population and are eligible for retreatment as a simplifying
assumption, as alternative dosing and treatment durations are
available for this group [32]. Nonetheless, over our relatively short
timescale (10 years) and with the low level of treatment examined
in this manuscript, simulations tracking nonresponders show that
negligible levels of infecteds are retreated [16].
Details and explanation of the model
We model the transmission of HCV amongst active IDUs, using
a system of ordinary differential equations simplified from [16,17].
We utilise a three compartment model, tracking susceptible,
chronically infected, and treated IDUs. Susceptible IDUs become
infected through sharing needles with infected IDUs. About one
quarter spontaneously clear the infection, and become susceptible
again. The remaining three-quarters progress to chronic infection.
Chronic infecteds can be treated, with a certain chance of success,
and either fail treatment and return to the infection compartment,
or clear the disease and become susceptible again.
In our model, X denotes the number of susceptible IDUs
(including those who have cleared the infection), C denotes the
number of both chronically infected and acutely infected IDUs
which will proceed to chronic infection, and T denotes the
number of IDUs in treatment, t is time in years, and where
N~total population~XzCzT . The equations describing the
HCV transmission are:
dX
dt
~h{p(1{d)
C
N
XzvaT{mX , ð1Þ
dC
dt
~p(1{d)
C
N
X{uCzv(1{a)T{mC, ð2Þ
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dT
dt
~uC{vT{mT , ð3Þ
with initial conditions X (0)~X0, C(0)~C0, T(0)~0. For the
initial conditions, we assume that the epidemic is at steady state
with no treatment, as is the case in most places in the UK [8].
Equation (1) represents the rate of change of the size of the
susceptible population, where new IDUs enter at a fixed rate h.
The second term in Equation (1) models the infection of
susceptible IDUs, which is proportional to the number of
susceptibles, the fraction of the population chronically infected,
and the infection rate p. The acute infection spontaneously clears
in a proportion d, who return to the susceptible pool. The
remaining infected fraction which do not spontaneously clear,
1{d, progress to chronic infection. The third term in Equation (1)
represents IDUs who exit treatment at a rate v, with successful
treatment proportion a.
Equation (2) models the rate of change of the number of
chronically infected IDUs. The first term represents those who
enter from the susceptible pool, which is proportional to the
number of susceptibles, the fraction of the population chronically
infected, the infection rate (p), and the fraction who do not
spontaneously clear the acute infection (1{d). The fraction of
nonresponders to treatment, (1{a), return from treatment
proportional to rate v.
The second term in Equation (2), {uC, represents the
movement of infected IDUs into treatment. The proportion of
infecteds put on treatment per year as an instantaneous rate
represented by u, can vary through time and is the function we
would like to optimise with respect to, given the constraints
described later.
Equation (3) represents the rate of change of the number of
IDUs currently in treatment. Infected IDUs enter treatment at the
rate u as discussed for Equation (2). IDUs exit treatment
proportional to the rate v.
In each of the populations, IDUs leave (due to death or ceasing
injection) proportional to the rate m.
System and Objective Functional
If we let x~
X
N
, c~
C
N
, t~
T
N
, so that the state variables are now
the fraction of the population in each compartment, then
Equations (1)–(3) become
dx
dt
~
h(1{x)
N
{p(1{d)cxzvat, ð4Þ
dc
dt
~p(1{d)cx{uczv(1{a)t{
hc
N
, ð5Þ
dt
dt
~uc{vt{
ht
N
, ð6Þ
where N evolves according to the equation
dN
dt
~h{mN: ð7Þ
Since the population is assumed to be in steady state, then
N~h=m. Making this substitution, Equations (4)–(6) become
dx
dt
~m(1{x){p(1{d)cxzvat, ð8Þ
dc
dt
~p(1{d)cx{uczv(1{a)t{mc, ð9Þ
dt
dt
~uc{vt{mt: ð10Þ
Since xzczt~1, we can substitute t~1{x{c into Equations
(8) and (9) and get rid of (10) so that we are left with the smaller
system
dx
dt
~mzva{(mzva)x{vac{p(1{d)cx, ð11Þ
dc
dt
~v(1{a)(1{x{c){uczp(1{d)cx{mc, ð12Þ
with initial conditions
x(0)~x0w0, ð13Þ
c(0)~c0w0, ð14Þ
where x0~mX0=h, c0~mC0=h and x0zc0~1. We wish to find
the function u(t) over the time horizon 0ƒtƒtf such that we
minimise the objective functional
J(u) :~
ðtf
0
½(b1zb2)ucNz(f1zf2)cNzcu2dt, ð15Þ
subject to the constraints
0ƒuƒ1, ð16Þ
b1ucNzcu
2ƒM, ð17Þ
where M is a positive constant representing the maximum
programme spend rate, and b1, b2, f1, f2 and c are the following
decreasing functions of time:
b1(t)~b10e
{rt, ð18Þ
b2(t)~b20e
{rt, ð19Þ
c(t)~c0e
{rt, ð20Þ
f1(t)~f10e
{rt, ð21Þ
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f2(t)~f20e
{rt: ð22Þ
The parameters b10, b20, c0, f10, f20 and r are positive constants.
The constant r is the instantaneous discount rate and can be
calculated using the formula
r~{log(1{r), ð23Þ
where r is the annual effective discount rate.
We divided the cost associated with HCV into two types. First,
we have the programme costs. These are the costs required to
search for and treat patients. Secondly, we have the costs
associated with infection. These are the costs incurred by the
health service when managing patients who are untreated and
remain infected. Together, programme (antiviral treatment and
search) and infection costs add up to the health service costs
associated with HCV. More precisely, the function b1 represents
the average cost of antiviral treatment per person. The search costs
related to finding, diagnosing, and recruiting active IDUs onto
treatment are represented by the term cu2. As is commonly done
in optimal control models of infectious diseases, we use a quadratic
function of the control to represent increasing marginal costs
associated with achieving high treatment coverage levels [24,33].
The function f1 represents the average annual infection cost per
chronically infected IDU.
To be able to incorporate health utility losses into the optimal
control framework, we monetarise the QALY losses associated
with HCV infection and antiviral treatment. We detail this
approach fully in the section ‘Economic parameters’. In particular,
b2 represents the monetarisation of the QALY loss per antiviral
treatment, and f2 represents the monetarisation of the QALY loss
per year associated with HCV. The parameters b10, b20, f10, and
f20 represent the initial values of these costs at t~0.
The first constraint 0ƒuƒ1 means that we cannot treat at a
rate higher than 100% of the infected population per year, and the
treatment rate cannot be negative. The second constraint
b1ucNzcu
2ƒM limits the spending rate of the treatment
programme (antiviral treatment and search costs) so that the
programme spending rate can never be greater than »M per year.
M will be referred to as the annual or yearly budget. As health
service costs related to infection, f1cN , are unrelated to the direct
programme budget, we do not incorporate these into the budget
constraint.
With our model, we project the optimal treatment programme
over time, the corresponding prevalence reductions and infections
averted with each programme, total programme costs, and total
infection costs. We divide our total programme costs by the
number of infections averted to calculate cost per infection
averted. We also calculate net monetary benefit (monetarised
benefits associated with QALYs gained minus net health services
costs) related to each programme compared to no treatment.
Finally, we calculate the health service cost per QALY gained for
each programme. Due to the prevention impact of antiviral
treatment, it is important to capture the future benefits of the
treatment programme. For these calculations, we simulate each 10
year treatment programme, and then continue calculating
discounted health service costs and QALYs for a further 40 years,
in order to determine the onward prevention impact of the
different 10 year treatment programmes. Hence, the total time
horizon in the cost per QALY gained calculation is 50 years. We
calculate the cost per QALY gained as compared to a baseline of
no treatment.
Optimal control
The optimal control problem is minu J(u) subject to (11)–(14),
(16) and (17). In other words, we seek the function u(t) such that
J(u) is minimised subject to the state equations (11) and (12), the
initial conditions (13) and (14) and the constraints (16) and (17).
We employ Pontryagin’s minimum principle [34] to determine
necessary conditions that must be satisfied by an optimal control, if
one exists. The existence of an optimal control and corresponding
optimal states is guaranteed for this optimal control problem as
criteria (a),(b),(c) of Theorem 4.1 and criteria (d’) and (e’) of
Corollary 4.1 found in [35, chap.3] are satisfied.
The optimal control theory associated with various types of
inequality constraints, including the ones considered here, can be
found in [36]. For a general introductory text on optimal control
methods applied to biological systems, we direct interested readers
towards the text by Lenhart and Workman [37]. The first step is to
form the Hamiltonian associated with this optimal control
problem, i.e.
H~(b1zb2)ucNz(f1zf2)cNzcu
2H
zlx(mzva{(mzva)x{vac{p(1{d)cx)
zlc(v(1{a)(1{x{c){uczp(1{d)cx{mc)
zL(b1ucNzcu
2{M),
ð24Þ
where lx, lc and L are functions of t. The multiplier L is an
adjoining Lagrange multiplier that must satisfy
L(t)§0, if b1ucNzcu2~M, ð25Þ
L(t)~0, if b1ucNzcu
2vM: ð26Þ
To find the characterisation of the optimal control, by Pontrya-
gin’s minimum principle we just need to find the u that minimises
the Hamiltonian. Since the control u appears quadratically in the
Hamiltonian, then to do this we simply set
LH
Lu
~0, ð27Þ
which gives the equation
(b1zb2)cNz2cu{clczb1cNLz2cuL~0: ð28Þ
If b1ucNzcu
2vM, then (28), with L~0 and the constraint (16),
provides the optimal control characterisation (call it u):
u~minfmaxf0, clc{(b1zb2)cN
2c
g,1g: ð29Þ
If b1ucNzcu
2~M, then the optimal control characterisation is
derived by simply solving this quadratic equation for u to obtain
u~minfmaxf0,
{b1cNz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(b1cN)
2z4cM
q
2c
g,1g, ð30Þ
where we have taken the positive root because the negative root
always yields a negative value of the fraction in (30) since the
parameters are all positive. Due to the control constraint (16), the
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optimal control is forced to lie within its admissible bounds 0 and
1.
We know from (26) that L~0 when the constraint (17) is not
tight. When the budget constraint is tight, the function L can be
determined from (28) with u~u as defined in (30), so that
L~
clc{2cu
{(b1zb2)cN
b1cNz2cu
 : ð31Þ
It is important to keep in mind that the search cost coefficient c
cannot at anytime be zero or else the optimal control problem is
singular. Singular optimal control problems require different
solution methods (see [38–40], and [37]).
The corresponding differential equations for the adjoint
variables (lx and lc) are determined from partial derivatives of
the Hamiltonian:
dlx
dt
~{
LH
Lx
, ð32Þ
dlc
dt
~{
LH
Lc
, ð33Þ
from which we obtain the adjoint equations
dlx
dt
~(mzva)lxzp(1{d)clxzv(1{a)lc{p(1{d)clc, ð34Þ
dlc
dt
~{(b1zb2)u
N{b1u
NL{(f1zf2)Nzvalx
zp(1{d)xlxzv(1{a)lc{p(1{d)xlczu
lczmlc:
ð35Þ
The adjoint equations have the final conditions
lx(tf )~0, ð36Þ
lc(tf )~0: ð37Þ
The state and adjoint equations and their four associated
boundary conditions constitute a two-point boundary value
problem which we solve in MATLAB using the forward-backward
sweep numerical method [37].
In order to force a specific final time prevalence, we must
remove the final time condition lc(tf )~0. Instead, an iterative
bisection method is used to find the value of lc(tf ) that yields the
desired final time target prevalence c(tf ).
Numerical solutions with a final time prevalence specified are
run with tf~10 years. Numerical solutions without a final time
prevalence specified are run with tf~50 years, and results
presented for the first 10 years. The use of an expanded time range
(tf~50) when there is no final time prevalence specified is
necessary to ensure that premature termination of treatment is not
recommended due to the lack of consideration for onward
transmission after the initial decade of interest. As new treatments
will likely be introduced in the next decade (with different cost
implications), it is reasonable to focus on a 10 year timeframe.
If instead we wish to simply minimise final time prevalence
subject to our budget constraint, we can do this by adding the term
wc(tf ) to the objective functional and making the positive constant
w very large, e.g. w~1010 so that the other terms in the objective
are negligible by comparison. Mathematically, this addition to the
objective functional leads to a different final time boundary
condition on lc, i.e. lc(tf )~w.
Uncertainty analysis
To examine how the uncertainty in the biological and cost
parameters alters the optimal control solution, we perform a Latin
Hypercube Sampling (LHS) of the cost parameters (b10, b20, f10,
f20, c0) and biological parameters (a1, a2=3, m and d) over a
uniform range of values. For each of the 100 parameter sets in our
sampling, we calculate the corresponding infection rate (p) and
new injector rate (h) which gives the desired untreated endemic
prevalence (30% or 45%), and retains a total of 1,000 IDUs in the
population. With each of these parameter sets, we calculate the
corresponding optimal control solution and infected prevalence
reduction.
Sensitivity analysis
A sensitivity analysis was performed to determine how sensitive
the infected prevalence is to variations in the epidemiological
parameters and in the presence of treatment. This allows us to
identify which parameters play the most significant role in the
disease dynamics, as well as how the prevalence sensitivity varies
between baseline prevalence scenarios. For the analysis, the
control function u is considered a constant function of time
ranging from zero to one. We then assess the variability in our
prevalence at 10 years (the timescale under consideration). We do
this by again utilising LHS to select 1,000 combinations of the
input parameters d, m, a1, a2 and u. For each set of parameters, the
infection rate, p, is then calculated given the untreated endemic
prevalence. The value for h is calculated from m to retain a total of
1,000 IDUs. We then solve the system of ordinary differential
equations using MATLAB, and track the projected prevalence at
year 10 with each parameter set. We then calculate a Partial Rank
Correlation Coefficient (PRCC) to assess the relative importance
of each parameter in determining infected prevalence. PRCCs are
widely used in sensitivity analyses in systems biology and disease
transmission models to determine the importance of a parameter
on a given output while fixing the other parameters at their
expected value [24,41–43]. The larger the absolute value of the
PRCC, the more influence a parameter has on prevalence, with a
PRCC magnitude greater than 0.5 and a p-value of v0.05
indicating the output is sensitive to changes in the input
parameter.
Discussion of parameter estimates
Biological parameters. We obtain the model parameters
from the relevant literature on injecting drug use and HCV
treatment as well as epidemiological data collected in the UK
(Table 1). We present results for two common baseline chronic
prevalences: 30% and 45% (approximately equivalent to 40% and
60% antibody prevalences, respectively). The exit rate is
determined by the sum of the cessation of injecting rate (calcu-
lated by using the average injecting duration) and the IDU death
rate. We use an average injecting duration of 11.5 years
(corresponding to a cessation rate of 8.7% per year) found in
[44]. This estimate for injecting duration is similar to an average
estimate across England and Wales, and so is likely to be
representative of many areas in the UK [45]. A recent study found
an IDU mortality rate (due to overdose, suicide, and other causes)
Optimal Control of Hepatitis C Treatment
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of 0.75% per year [46]. The rate of IDUs entering the population
is calculated from the exit rate to retain 1,000 IDUs in the
population.
Treatment duration and success depends on the specific genotype
of HCV being treated. In general, SVR is high for IDUs with
genotype 2 or 3 (75–85%), and lower for genotype 1 (40–50%)
[9,11,13,47]. The recommended duration of treatment for genotype
2/3 is 24 weeks for both responders or nonresponders, and for
genotype 1 the duration is 48 weeks for responders and 12 weeks for
nonresponders [11,13]. In the United Kingdom, about half of the
infections are genotype 1, with the remaining half 2 or 3 [11].
Hence, we take an average between the genotype 1 and 2/3
parameters for the treatment success parameter (a), as well as the
treatment duration (1=v). Finally, [29] performed a meta-analysis
and found that 26% of infections lead to spontaneous clearance,
which we use for the parameter d. The parameter p is determined
for the two different prevalence scenarios by assuming that HCV
amongst IDUs is in steady state, a reasonable assumption for HCV
amongst IDUs the UK [44].
Economic parameters. A summary of the economic
parameters can be found in Table 2, with the specific maximum
annual budgets considered shown in Table 3. Programme treatment
costs are constructed from current drug price estimates and costing
studies. Depending on the type of peginterferon alfa used (2a or 3b)
and body weight, the drug costs of combination peginteferon and
ribvirin treatment is between »12,496–14,221 per person [11]. In
addition to drug costs, we include patient evaluation, tests,
screening, and consultations during and after treatment. Cost-
effectiveness analyses for HCV treatment have estimated these total
costs to be »760 (in 2008/2009 GBP) for investigations of a patient
who is considered for treatment, and »810.32–1,084.30 for
consultations depending on treatment length [12]. Therefore, the
total costs of delivering antiviral treatment are »14,066–16,064 per
year, and we use a mean value of »15,065 per year, varying this in
the uncertainty analysis. We calculate the cost per treatment by
multiplying the yearly treatment cost (which we denote byr) and
average treatment duration (1/v).
The parameter c0 represents the cost of ensuring 100%
treatment coverage in the first year, which would involve an
extensive testing and recruitment programme. Programme search
costs are difficult to estimate, as there is no published literature on
cost analysis of IDU recruitment to services by coverage level.
Systemic reviews examining costs of vaccination scale-up pro-
grammes show a lack of good methodological studies and rigorous
cost analyses [48–50]. Nevertheless, it is reasonable to assume
increasing marginal cost when attempting to increase coverage to
high coverage rates, due to the assumed increased difficulty in
recruitment and uptake [33]. All IDUs would need to be antibody
tested. The cost of a dried blood spot antibody test is
approximately »19.84, so »19,840 in a population of 1000 IDUs.
The additional cost of RNA PCR for those who are chronically
infected and will enter treatment is incorporated in the antiviral
treatment costs. About one quarter of those who are antibody
positive have spontaneously cleared the acute disease, and would
need a PCR test to confirm their negative status. At worst, in our
population of 30–45% prevalence, this amounts to about 150
IDUs per year. At a cost of »70.77 for the PCR test, the maximum
cost of PCR testing is »10,615.
With current dried blood spot testing technology, HCV testing
can be implemented by local outreach services (such as needle and
syringe programmes), however the implementation of an intensive
testing programme would likely require staff and training, and
potentially overheads. There is no published cost estimation for
needle and syringe programmes (in particular training and staffing)
in the UK [51] so estimates were taken from two other countries
(Canada and Ukraine) and costs translated to the UK using the
2009 Purchasing Power Parity (PPP) Index provided by the World
Bank [52]. Jacobs et al. [53] reported the yearly cost to run a local
needle and syringe exchange programme (including staff, training,
and overheads, but excluding syringe costs) in Edmonton, Canada
as $253,553 CAD (2009). The programme distributed 565,754
needles in a year, but did not document the number of visits per
year. No estimates were given for the number of needles distributed
at a time, however the mean number of syringes collected per
contact has been estimated at around 20 [54], leading to
approximately 28,288 contacts per year, or $8.96 CAD per contact.
Using the 2009 PPP conversion factor (approx. 1.76) [52] and the
average exchange rate in 2009 (1.78 CAD to 1 GBP, www.x-rates.
com), this results in an average cost per contact of »8.86 (2009). In
this study, a local van was used for outreach, which is likely similar
to the kind of programme which would be used in the UK if the aim
was to attain high coverage. We therefore use it as the base for our
programme cost estimation.
A similar analysis on data from the first year of a needle and
syringe programme in Ukraine [55] includes building purchase and
construction costs, giving a higher cost per contact of »22.10 (2009).
Of this amount, nearly 25% is comprised of the first year capital
non-reoccurring costs. However, this is likely to be an appropriate
upper bound as in subsequent years, especially in situations
targeting high coverage or with low prevalence, a media campaign
might be necessary. Hence, the repeated inclusion of this 25%
excess cost (for capital, media, or other) seems appropriate.
Table 1. Biological parameter values used in the numerical simulations.
Parameter Definition Value Units Source
a Proportion infections cured by treatment 0.625a - [11,13]
v 1/treatment duration 1.992b per year [11,13]
d Proportion infections spontaneously clear 0.26 - [29]
p Infection rate 0.1834–0.2334 per year Fit to 30% and 45% infection prevalences [44]
m Exit rate (through death or cessation) 0.095c per year [44–46]
h New injector entrance rate 95 per 1,000 IDUs annually Given value to retain population of 1,000 IDUs
aAverage of the genotype 1 cure rate (a1~0:45) and the genotype 2/3 cure rate (a2=3~0:8).
bExit rate calculated from the average of the genotype 1 treatment length for responders and nonresponders: (a1|48z(1{a1)|12) weeks and the genotype 2
treatment length, 24 weeks.
cBased on a cessation rate of 8.7% per year, and an IDU death rate of 0.75% per year.
doi:10.1371/journal.pone.0022309.t001
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In total, for u~1 (treating at a rate of 100% of the IDU
population per year), the total cost of programme outreach and
testing of 1,000 IDUs would be »39,315, with a maximum
estimate of »52,555. We therefore use c0~»40,000 and vary this
from »39,000 to »53,000 in the uncertainty analysis.
The infection costs (f10) associated with a person with mild to
moderate chronic HCV are approximately »657 per year [12,56].
These costs escalate markedly in the later stages of disease, but
given the long timescale of disease progression to cirrhosis
(decades) and the average injecting duration (approximately 11
years) it is assumed all infected active IDUs are either in the mild
or moderate stage.
In order to quantify the quality of life reduction for active IDUs
with HCV and for active IDUs with HCV undergoing treatment,
Table 2. Economic parameters.
Parameter Definition Scenario Value Source
b10 Antiviral treatment costs per treatment all »15,065=v [12,56,73]
b20 Monetarised QALY loss per treatment A, B »5,800=v See text
C »0 -
f10 HCV infection costs per year all »657 [12,56,73]
f20 Monetarised QALY loss for HCV per year A, B »3,800 See text
C »0 -
c0 Recruitment and testing cost (per year per unit u
2) all »40,000 Little data, see text [53,55]
r Discounting rate for costs and health utility losses (annual) all 3.5% [60]
M Maximum annual budget (per 1,000 IDUs) all »50,000–300,000 -
Scenario A: minimising health service costs and HCV health utility losses (measured in monetarised QALY loss). Scenario B: minimising health service costs and HCV
health utility losses with a final time prevalence target. Scenario C: minimising only health service costs with a final time prevalence target.
doi:10.1371/journal.pone.0022309.t002
Table 3. Net costs, net QALYs gained, and cost per QALY gained as compared to no treatment programme for the 30% and 45%
HCV prevalence scenarios and various optimisation programmes.
30% HCV prevalence 45% HCV prevalence
Scenario
Max annual
budget (»)
Net
costs1 (»)
Net QALY
gain2
Cost (») per
QALY gained
Net
costs1 (»)
Net QALY
gain2
Cost (») per
QALY gained
A 50,000 220,028 135 2148 - - -
100,000 299,210 287 2346 - - -
150,000 2256,459 462 2555 327,996 293 1,120
200,000 2520,789 668 2780 359,397 413 870
250,000 - - - 332,703 550 605
300,000 - - - 227,253 710 320
B 50,000 - - - - - -
100,000 249,338 203 2243 - - -
150,000 246,459 216 2215 288,304 233 1,237
200,000 244,793 224 2200 316,510 251 1,263
250,000 - - - 335,742 263 1,277
300,000 - - - 349,527 272 1,285
C 50,000 - - - - - -
100,000 240,348 159 2254 - - -
150,000 233,130 145 2228 213,173 179 1,192
200,000 223,268 137 2169 190,679 163 1,167
250,000 - - - 183,950 154 1,192
300,000 - - - 183,212 148 1,239
The optimal 10 year programme is determined for each scenario, and then costs and QALYs are calculated for a further 40 years (for a 50 year time horizon) in order to
account for the onward prevention benefits of the treatment programme. Scenario A: minimising health service costs and HCV health utility losses (measured in
monetarised QALY loss). Scenario B: minimising health service costs and HCV health utility losses with a final time prevalence target. Scenario C: minimising only health
service costs with a final time prevalence target.
1Net costs = health care costs over 50 years with the 10 year treatment programme - health care costs over 50 years with no treatment. Health care costs are defined as
programme (antiviral treatment and search) costs as well as HCV infection related costs.
2Net QALY gain =QALYs gained over 50 years with the 10 year treatment programme - QALYs gained over 50 years with no treatment.
doi:10.1371/journal.pone.0022309.t003
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we monetarise the QALY loss in each case. This approach
excludes non-health benefits associated with the intervention (such
as impact on productivity), but nonetheless allows us to arrive at an
estimate of the net monetary benefit of the programme. In the
UK, this is possible using the ‘willingness-to-pay’ threshold defined
by NICE, which essentially determines the amount the UK’s
National Health Service is willing to pay for a treatment. The
current willingness-to-pay threshold (i.e. the UK’s monetarised
value of a QALY) is approximately »20,000 per QALY gained
[57]. Estimates for the health state for a non- or ex-IDU with mild
chronic HCV infection are around 0.78 QALYs per year,
depending on the evaluation method [12]. Healthy active IDUs
tend to have a lower baseline quality of life than non- or ex-IDUs,
with estimates at around 0.85 QALYs per year [56], i.e. a 15%
reduction in quality of life from the healthy non-IDU state. We use
this 15% reduction to calculate the health state reduction for active
IDUs with HCV, in line with other economic evaluations of HCV
in active IDUs [56]. Hence, we estimate that the health state for
an active IDU with HCV is 0.66 QALYs per year, i.e. an absolute
reduction of 0.19 QALYs per year from the healthy active IDU
state, meaning that the (monetary) benefit from successfully
treating a chronically infected IDU is approximately »3,800 per
year (0.19 QALYs/year|»20,000/QALY). In other words,
»3,800 is the estimated monetary benefit foregone per year by
not treating an infected IDU, hence it is essentially an opportunity
cost, represented by the monetarised value of QALYs lost due to
non-treatment. On the other hand, being on HCV antiviral
treatment also results in a QALY reduction (from infection level)
of about 0.10 QALYs per year for the duration of treatment [12],
hence we assume the net reduction from the healthy active IDU
state to an active IDU with HCV on treatment is approximately
0.29 QALYs per year, and therefore the cost in terms of
monetarised value of QALYs lost due to treatment is approxi-
mately »5,800 per year. These monetarised values of QALYs lost
due to either infection or treatment make up the HCV health
utility losses. Due to the lack of evidence surrounding utility values
following treatment of those with mild (in particular, asymptom-
atic) HCV, we use published estimations that SVR from mild
HCV results in a return to the normal health state [58,59].
Health costs and utility losses are discounted at an annual
effective rate of 3.5% per year, meaning that our cost weights
decrease through time [60]. This allows for the correct cost
adjustment when using a maximum implementation yearly
budget. All costs are presented in UK pounds (GBP, ») in fiscal
year 2008/2009 values and updated with the Hospital and
Community Health Services Pay and Prices Index [61]. We
examine several budget scenarios, from a maximum yearly budget
of »50,000 to »300,000 per 1,000 IDUs.
Parameter ranges for the uncertainty analysis. During
the uncertainty analysis, each parameter is taken to be uniformly
distributed, with ranges as shown in Table 4 for the biological
parameters varied. For the cost parameters, the ranges for b10, b20,
f10, and f20 were taken to be plus and minus 10% of the values
given in Table 1. Due to the high uncertainty in c0, the range used
was from »39,000 to »53,000.
Results
If only health service costs are minimised (with no requirement
to reduce health utility losses or reach a final time prevalence
reduction), the optimal solution is to treat no one. In each of the
scenarios considered below, we add further considerations to this
baseline case.
Scenario A: Minimising health service costs and HCV
health utility losses (f2,b2w0)
This scenario represents an ‘ideal’ situation, where policymakers
are motivated to minimise health service costs and health utility
losses associated with HCV, limited only by budget restrictions.
The optimal programme is to spend the maximum possible
amount each year on the treatment programme, which succeeds in
reducing infections and QALY losses.
If the objective is to minimise health service costs and health
utility loss related to HCV infection, Figure 1 shows the potential
impact of the optimal treatment programmes for various
maximum yearly programme budgets with a 30% baseline
prevalence. In all budget scenarios, the optimal number treated
increases over time, due to the discounting treatment costs and
subsequent ability to increase treatment allocation. Figure 1 shows
that depending on the maximum annual budget (»50,000 to
»200,000 per 1,000 IDUs annually), the number of treatments
allocated yearly varies from 7 to 37. With a »100,000 maximum
annual programme budget, the prevalence decreases from 30% to
about 21% at year 10 with a total of 43 cases (per 1,000 IDUs)
averted. This equates to a total programme spend per infection
averted of »23,597. The infection related costs reach »1.42 million
by 10 years. Net monetary benefit at 10 years is »291,088. The
cost per QALY gained with a 50 year time horizon is 2»346, with
negative net costs and positive net QALYs gained as compared to
no treatment, indicating that the programme is cost saving
(Table 3).
Table 4. LHS sensitivity analysis on the model with constant control (n~1,000).
Parameter Range (Min, Max) Source PRCCa 10 yr prevalence (30% baseline) PRCCa 10 yr prevalence (45% baseline)
a1 (0.40, 0.50)
b [11,13,47] 20.6839* 20.6904*
a2=3 (0.75, 0.85)
b [9,11,13] 20.7153* 20.6762*
m (0.05, 0.1429)c [44–46,74] 0.4271* 0.7234*
u (0, 1) - 20.9992* 20.9990*
d (0.22, 0.29) [29] 20.0387 20.0338
aPartial Rank Correlation Coefficient,
ba is calculated as an average of the genotype treatment success rates, a1 and a2=3 .
cThe exit rate is calculated from the range of the genotype 1 treatment length for responders and nonresponders: (a1|48z(1{a1)|12) weeks and the genotype 2
length: 24 weeks.
*denotes a p-value of below 0.05.
doi:10.1371/journal.pone.0022309.t004
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When the budget constraint is increased to »200,000 per year,
the prevalence decreases to below 12% within a decade.
Additionally, 96 infections are averted by 10 years, resulting in a
reduction in cost per infection averted to »20,945. As compared to
the lower budget scenario, the increased programme costs are
partly offset by reduced infection-related costs of »1.17 million at
10 years. Net monetary benefit increases to »630,111. Addition-
ally, increasing the budget saves more in terms of cost over a 50
year time horizon and gains more QALYs, resulting in a cost per
QALY gained of 2»780, indicating that this programme is more
cost-effective than one with a lower budget (Table 3). Results are
qualitatively similar for the 45% baseline prevalence scenarios,
however with the same yearly budget the relative reduction in
prevalence is smaller, there are fewer infections averted, and the
cost per averted infection is higher (Supporting Information Figure
S1). Furthermore, the programme results in fewer QALY gains,
and the cost per QALY gained is higher, at »870 (Table 3).
Overall, increasing the yearly budget results in greater short-
term reductions in prevalence, increased infections averted, lower
programme cost per infection averted, and substantial reductions
in infection related costs at year 10 due to the subsequent
prevention effect. For a given yearly budget, the impact is higher
in lower prevalence areas.
The optimal programme strategy and results presented above are
identical if the objective is instead to minimise prevalence at the end
of year 10 while being constrained by the same budget restrictions.
In other words, the programme which minimises prevalence at the
end of year 10 is the one where the entire budget is spent every year,
and this strategy also has the lowest cost per QALY gained.
Scenario B: Minimising health service costs and HCV
health utility losses with a final time prevalence target
(f2,b2w0, c(tf )~0:8c0)
In a less ‘ideal’ scenario, policymakers could be motivated by a
political constraint as well, and specify a need to reduce prevalence
by a specific amount within 10 years. Therefore, in this case we
examine the optimal timing and intensity of a programme where
the desire is to achieve a specific prevalence reduction by the final
time, while also minimising total health service costs and HCV
health utility losses. These objectives are again constrained by
yearly budget restrictions. In these simulations, the final time
prevalence is specified as a necessary condition, such that the
prevalence at tf~10 years is reduced by a relative 20% (so, from
30% to 24% or 45% to 36%).
Numerical solutions indicate that the best strategy with a final
time target including costs related to health state reductions is an
initial, intense programme (Figure 2). In the 30% baseline
prevalence scenario, the »50,000 maximum budget scenario is
not sufficient to result in a 20% relative reduction in prevalence.
With an annual budget of »100,000, the optimum is an 8 year
programme of increasing treatment coverage (expanding from 4%
to 8% of infected IDUs), treating 13–17 people per year in the first
seven years where the full budget is spent, and 7 people in the
eighth year (Figure 2). This programme results in an initial swift
decrease in prevalence, slightly overshooting the 10 year target
prevalence in year 8, and eventually rebounding to the target by
the end of year 10. The programme averts 37 infections resulting
in a programme cost per infection averted of »19,888. The total
costs of the programme (treatment and search) reaches just over
»740,803 with the infection related costs reaching »1.44 million. In
this scenario, net costs as compared to no treatment are still
negative, but fewer QALYs are averted as compared to Scenario
A, and cost per QALY gained is higher at 2»243, however the
programme is still cost-saving (Table 3).
Increasing the budget to »200,000 decreases the duration of the
optimal programme to five years, with a lower level of treatments
(26–30) for the first four years, tailing off with 5 treatments in the
fifth year. This strategy increases the programme cost to »830,051,
but averts more infections (50 by year 10), resulting in a lower
programme cost per infection averted of »16,737. Furthermore,
the infection related costs are reduced to »1.36 million. However,
the cost per QALY gained is slightly higher than in the lower
budget scenario, at 2»200 due to the higher programme cost
(Table 3).
With a 45% baseline prevalence scenario, the optimal pro-
gramme is still an initial programme, but the programme duration
to reduce prevalence by 20% is longer (Supporting Information
Figure S2). With an annual budget of »200,000, the programme
spans 7 years instead of the 5 years in the lower prevalence scenario.
Total programme and infection costs are substantially higher, at
»1.35 million and »2.1 million, respectively. Additionally, fewer
infections are averted (40 in 10 years), and the cost per infection
averted is nearly double that of the 30% prevalence scenario.
Similarly, the cost per QALY increases to »1,263 (Table 3).
Scenario C: Final time prevalence reduction only
(f2~b2~0, c(tf )~0:8c0)
In the least ‘ideal’, but perhaps most relevant and ‘real-world’
scenario, policymakers may be motivated solely by a political
commitment to reduce prevalence by a specific amount, neglecting
the loss of health utilities associated with infection. As compared to
Scenario B, where there is a bias towards early and intensive
treatment to reduce the cumulative number of infections,
neglecting health utility losses results in very different optimal
programmes (Figure 3). In the 30% prevalence scenario, with a
maximum budget at »200,000 per year, the optimal programme is
implemented in the final three years only, increasing treatment
coverage from 11% to 16%. This results in treating 13–36 people
per year, costing the programme only »478,369, but infection costs
reach »1.62 million. Since the costs associated with infections are
much lower when neglecting loss of health utility, the optimal
strategy shifts toward achieving the target prevalence with fewer
treatments, whereas with health utility losses included in the
objective, the optimal strategy seeks to decrease a greater number
of the infections by treating earlier instead of later. Hence, the
number of infections averted is only 8 per 1,000 IDUs at year 10,
and the cost per infection averted is substantially increased to over
»62,324. Importantly, in this scenario, the programme does not
result in a net monetary benefit at 10 years, with costs exceeding
benefits throughout the decade. The cost per QALY gained
(2»169) is slightly higher than Scenarios A and B, with fewer
QALYs gained, and higher costs (Table 3).
Decreasing the yearly budget to »100,000 results in a longer
programme, lasting years 5 through 10, increasing treatment
coverage from 5% to 8%. Reducing the budget increases pro-
gramme costs (to »560,241), but decreases infection costs to »1.57
million. Furthermore, decreasing the maximum annual budget
increases the treatment programme duration, resulting in more
infections averted (nearly 16 per 1,000 IDUs by year 10).
Additionally, the cost per infection averted is substantially less,
at just over »35,087. This indicates that although a higher annual
budget can achieve the same prevalence reduction with a shorter
programme duration, achieving earlier prevalence reductions (for
example, by treating fewer but initiating the programme earlier)
results in more infections averted and a reduced cost per infection
averted. The qualitative shape of the programme (delayed until
final years) is unchanged if discounting is neglected.
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For the 45% prevalence scenario, the optimum is also a late
initiated programme, but with a longer programme duration to
achieve the target prevalence (Supporting Information Figure S3).
The programmes begin in years 4–8 and escalate until the final year.
Cumulative programme costs are roughly equal (at the »200,000
annual budget) and 15% higher (at the »150,000 annual budget) than
in the 30% prevalence scenario, and the cost per QALY gained is
higher than in scenarios A and B, or for any of the low prevalence
scenarios, at about »1,200.
Uncertainty analysis of optimal control solution
The impact of uncertainty of our parameters on the optimal control
and prevalence reductions for various maximum budget scenarios are
Figure 1. Scenario A: Minimising health service costs and HCV health utility losses. Simulations are with a 30% baseline prevalence,
showing (A) programme coverage, (B) prevalence reductions, (C) number of treatments, (D) total health service costs (comprised of programme costs
and infection costs), (E) infections averted, and (F) net monetary benefit. Parameters used are as shown in Tables 1–2, with f20~3,800,
b20~5,800|(1=v), tf~50, and with no final time prevalence constraint.
doi:10.1371/journal.pone.0022309.g001
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shown in Figure 4 for 30% baseline prevalence and maximum yearly
budget of M~»150,000 with and without the final time prevalence
target (including monetarisation of QALYs). The results for 45%
baseline prevalence with a maximum annual budget of M~»200,000
are shown in Figure S4 of the Supporting Information. Despite the
uncertainty in both the biological and economic cost parameters, the
qualitative results remain unchanged, with only small variations of at
most two years in the duration of treatment programme.
Sensitivity analysis
The results of the sensitivity analysis are found in Table 4,
which shows how sensitive the 10 year prevalence is to changes in
Figure 2. Scenario B: Minimising health service costs and HCV health utility losses with a final time prevalence target. Simulations are
with a 30% baseline prevalence, showing (A) programme coverage, (B) prevalence reductions, (C) number of treatments, (D) total health service costs
(comprised of programme costs and infection costs), (E) infections averted, and (F) net monetary benefit. Parameters used are as shown in Tables 1–2,
with f20~3,800, b20~5,800|(1=v), and a final time prevalence constraint.
doi:10.1371/journal.pone.0022309.g002
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the epidemiological parameters. Here, we assume the treatment
rate is constant through time. This allows for the assessment of
which parameters to which the prevalence is most sensitive. In
both prevalence scenarios, the endemic prevalence is most
sensitive to the treatment rate, which indicates that treatment
could play an important role in reducing prevalence. The 45%
prevalence scenario is then most sensitive to the exit rate (m),
followed by the treatment cure rates (a1,2=3). By contrast, the 30%
prevalence scenario is more sensitive to the treatment cure rates
than exit rate. This indicates that at higher prevalences, variations
in injecting duration between sites can significantly alter impact
projections; at lower prevalences variation in injecting duration
Figure 3. Scenario C: Minimising only health service costs with a final time prevalence target. Simulations are with a 30% baseline
prevalence, showing (A) programme coverage, (B) prevalence reductions, (C) number of treatments, (D) total health service costs (comprised of
programme costs and infection costs), (E) infections averted, and (F) net monetary benefit. Here, we neglect health utility losses. Parameters used are
as shown in Tables 1–2, with f20~0, b20~0, and a final time prevalence target constraint.
doi:10.1371/journal.pone.0022309.g003
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would have less of an impact on prevalence at 10 years. As the
sensitivity coefficient of the exit rate is positive, increasing the
injecting duration would lead to an increase in prevalence.
Conversely, increasing treatment cure rates lead to decreasing
prevalence. The sensitivity results indicate that in high prevalence
scenarios, aside from antiviral treatment, initiatives reducing
injecting duration would have the most effect on reducing
prevalence. Notably, in both prevalence scenarios the 10 year
prevalence is not sensitive to the variation in the spontaneous
clearance rate. Hence, for example, a 10% change in spontaneous
clearance would have substantially less of an impact on prevalence
than the same percent change in injecting duration.
Discussion
Main Findings
We use optimal control theory to determine the optimal timing
and intensity of an HCV antiviral treatment programme for active
IDUs with a variety of policy objectives, budget constraints, and
prevalence settings. The aim is to aid in the design and
implementation of treatment programmes aimed at targeting
active IDUs and utilising antiviral treatment as a prevention
strategy. From a public health and economic perspective, if there is
a fixed yearly budget then the ideal strategy is an immediate
programme of maximum intensity, with the maximum budget
constraint spent each year on treatment. This minimises health
service costs and HCV health utility losses. This results in high
health service costs, but high numbers of infections averted (up to
90 per 1,000 IDUs for the budgets considered) and substantial (up
to 60%) reductions in prevalence at 10 years, depending on annual
programme budget and prevalence. At an HCV chronic
prevalence of 30%, the 10 year programme is cost-saving over a
50 year time horizon, and has the lowest cost per QALY gained as
compared to other scenarios due to the substantial prevention
benefit. For the same annual budget, a higher baseline prevalence
results in higher costs per QALY gained, and the programme is no
longer cost saving (though well below the willingness-to-pay
threshold), as the prevention impact is less. Increasing the annual
programme budget results in greater short-term (10 years)
reductions in prevalence, reduced cost per infection averted,
substantial reductions in infection-related costs, and greater cost-
effectiveness (lower costs per QALY gained) due to the subsequent
prevention effect. Since the costs per QALY gained are below the
current willingness-to-pay thresholds for the UK and elsewhere
(»20,000–30,000 per QALY gained), these results suggest that
increasing the budget allocated to HCV treatment amongst IDUs
would be an improved strategy.
A programme may have a policy objective of reducing HCV
prevalence by a certain amount over 10 years. In this case, the
optimal programme implementation strategy changes substantially
depending on whether or not there is a further objective of
minimising the health impact of the disease (measured by
monetarised QALY loss). If the policymaker desires to minimise
the loss of health utility related to HCV infection in addition to
Figure 4. Uncertainty analysis results for optimal control. Simulations are shown for Scenario A (top) and Scenario B (bottom). The baseline
prevalence is 30%, and maximum yearly budget is limited to M= »150,000. The cost coefficients b10, b20, f10, f20 are uniformly distributed with means
given in Table 1 and the ranges given by plus and minus 10% of the means. The range for c0 is »39,000–53,000. The parameters a1, a2=3 , m and d are
uniformly distributed with the ranges given in Table 4.
doi:10.1371/journal.pone.0022309.g004
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health service costs, the optimal strategy is to gradually increase
coverage over the first part of the decade and then stop after the
desired prevalence is reached. This immediate, but shorter
programme reduces the cost of the treatment programme, but
increases HCV infection hospital costs and averts fewer infections.
Therefore, although the programme achieves its policy objective
(to reduce prevalence by 20%), it fails to have the full prevention
impact and is less cost-effective (though still well below the cost-
effectiveness willingness-to-pay threshold) than the previous
scenario which did not have a prevalence target. With this
programme, increasing the annual budget results in more
infections averted, but a higher cost per QALY gained due to
the slightly higher programme costs.
However, where policymakers are motivated only by achieving
the target prevalence reduction with minimum health service costs
(and do not consider HCV health utility losses) then the optimal
timing of scale-up changes substantially. In this case, the ‘optimal’
programme is to delay initiating the treatment programme until
the final few years, resulting in the desired prevalence reduction
but with lower programme costs. However, this delayed
programme results in many fewer infections averted, higher costs
per infection averted, and higher HCV infection-related costs.
This indicates that implementers who neglect the loss of health
utilities associated with being HCV infected but only consider
health service costs may plan the programme in such a way that it
reduces its cost-effectiveness. The ‘optimal’ programme includes
treatment only because of the required prevalence reductions.
Moreover, in this scenario, increasing the maximum budget
reduces programme duration and decreases health services costs
but results in fewer infections averted, and increased cost per
infection averted. Hence, in this scenario a lower budget
programme results in greater impact and programme cost-
effectiveness. Finally, all our scenarios show, with a fixed annual
budget, greater impact (measured by infections averted, or
prevalence reductions) and cost-effectiveness will be achieved in
lower prevalence areas.
Strengths and limitations
The use of optimal control theory in public health programme
delivery and design is still relatively unexplored. As such, there are
a number of methodological issues mentioned in this paper which
need to be addressed before real-world implementation of this
technique. First, we assume a quadratic search cost function, to
reflect the increasing unit costs related to recruitment and testing
with higher programme coverage. Although studies have shown
that in many cases these unit costs are not linear [62–65], the
precise shape of this curve (be it quadratic, cubic, or other) is still
unclear, and likely varies between situations. We assume that costs
for a given coverage level are equal for different baseline
prevalence scenarios, although it is possible that search costs for
a given treatment coverage could be lower in different settings.
Further research into the most accurate form of this cost function,
as well as how it varies in real-world settings, would strengthen the
confidence in the specific predictions of the model.
Second, the actual costs associated with the scale-up of
treatment coverage are difficult to estimate, and likely vary
considerably depending on target population and current coverage
level. Most traditional cost analyses neglect the additional costs
related to increased coverage and recruitment, but these costs can
often be significant. Proper quantification of costs related to media
campaigns, outreach networks, and testing coverage would
strengthen this analysis. In particular, it is likely that the costs of
increasing coverage vary depending on baseline coverage level,
target population, and population size. Additional studies
quantifying costs related to identifying a greater proportion of
the hidden IDU community, and expanded testing and treatment
recruitment would aid in parameterising future economic models.
Third, given the lack of clinical studies examining the potential
effect of antiviral treatment to prevent transmission of HCV
amongst active IDUs, our study is based on a previously developed
mathematical model. Therefore, the findings are based on model
projections of the treatment effect and not experimental evidence.
Furthermore, the underlying disease transmission model neglects
heterogeneity within the injecting drug user population, which
may alter the efficacy of a treatment programme and the
quantitative projections presented here. For example, shifts in
genotype distribution may serve to increase/decrease programme
efficacy. Additionally, it is highly likely there will be heterogene-
ities in treatment presentation, completion, and post-treatment
behaviour and risk, among individual IDUs and also at different
times during an individual’s injecting career. Unfortunately, there
is insufficient evidence to parameterise this heterogeneity, which
can only be incorporated once additional clinical evidence has
been collected.
Fourth, it is also important to note that we assume a constant
population of active IDUs, which is an appropriate approxima-
tion in the UK, but may not apply to settings such as the
Netherlands, which has a shrinking IDU population due to a
reduction in incidence of new injectors. However, many countries
do not have a declining population, primarily because given the
prolonged duration of injecting, changes in incidence take a long
time to be observed in changes in prevalence [66]. Nevertheless,
further studies could explore the impact of relaxing this
assumption and apply the model to areas with a nonconstant
population size.
Fifth, the cost per QALY gained estimates have several
limitations. Most notably, the model does not track former IDUs,
and therefore underestimates the QALYs gained after cessation of
drug use by those who are treated or prevented from infection
while active IDUs. A detailed economic evaluation aimed at
evaluating the cost-effectiveness of treating active IDUs would
therefore include subsequent HCV disease states often reached
after cessation of drug use (cirrhosis, hepatocellular carcinoma,
liver transplant, etc.) and calculate detailed costs and QALYs for
each state. There is also considerable uncertainty surrounding
QALY fractions for active IDUs (either uninfected or HCV
infected), and a full economic evaluation of treatment in active
IDUs would need to address this uncertainty, which we have
neglected.
Finally, we neglect any additional health costs due to non-HCV
related illness resulting from increased lifespan from successful
HCV antiviral treatment. Previous economic evaluations of HCV
antiviral treatment have neglected additional costs or QALY losses
due to non-HCV related diseases which may occur due to
increasing lifespan, and we make a similar assumption [12].
However, if these costs and QALYs could be quantified, the
inclusion would provide a fuller picture of cost-effectiveness.
Furthermore, due to the focus on current IDUs only, we neglect
costs and utilities associated with HCV progression past the mild
or moderate state. We believe this is an appropriate first
assumption, as any programme targeting IDUs who are actively
injecting is likely to treat the disease at the mild stage which would
result in minimal future HCV-related health service costs.
However, it is possible that an increase in life-expectancy could
accrue additional costs, particularly if broader societal costs (such
as those related to injecting drug use) are included. Unfortunately,
the lack of data relating to how antiviral treatment of IDUs alters
injecting behavior and subsequent societal costs makes this difficult
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to include in an analysis. Future work quantifying the cost and
impact of treatment on IDU behaviour would enable a more
detailed study than the work presented here.
Evidence from other studies
There is an established body of literature describing the use of
optimal control theory on biological systems [67–72], with some
applications towards control measures for infectious diseases [24–
27]. To our knowledge, this is the first application of this
technique to the control of HCV amongst injecting drug users.
The use of antiviral treatment as prevention of HCV amongst
IDUs has been proposed by several modelling studies [16–19],
but the experimental or clinical data are limited and probably
subject to considerable selection bias. Nevertheless, the available
evidence suggests that IDUs can be treated successfully,
indicating the potential for using antiviral treatment as a control
measure.
Implications and future work
Despite the application of a number of prevention measures,
HCV remains an important public health concern in the IDU
population. Antiviral treatment for HCV has been established as
effective and cost-effective, but uptake of therapy remains low
among active IDUs, and is rarely encouraged. Our previous
modelling work has shown that antiviral therapy could play a
valuable role in controlling the HCV epidemic amongst IDUs.
Despite this, treatment rates among IDUs remain low (less than
1%) even in countries such as the UK and Australia where
treatment is recommended under a national health care system.
Recently, several action plans have been developed which aim to
allocate specific resources to initiating HCV treatment pro-
grammes [20–22], though none specifically aimed at active IDUs
and for the expressed purpose of prevention. There is increasing
interest in developing treatment programmes aimed at treating
active IDUs for prevention [23], and as such we aimed to
determine the optimal timing and intensity of an HCV antiviral
treatment programme for active IDUs, given various resource,
policy, and prevalence constraints and objectives as could be
seen in the real world. We find that incorporating different
budget constraints and policy objectives plays an important role
in determining the optimal programme structure, and subse-
quent programme cost-effectiveness (measured by cost per
QALY gained). Extensions of our current model will explore
the optimal allocation of the currently available prevention
options (such as needle and syringe programmes and opiate
substitution therapy) given resource constraints, in order to best
combat the spread of HCV amongst injecting drug users. This
could inform policymakers on which interventions to spend
money first, if alternating interventions is the best strategy, or
how specific combinations of interventions at different stages
could best combat the disease.
Though used widely in other disciplines, the use of optimal
control theory with reference to public health programme
implementation and resource allocation is fairly limited. Most
optimal resource allocation models only focus on optimal
allocation at a single timepoint, while optimal control theory
allows for the optimal allocation to change continuously over time.
We believe this powerful technique could play a key role in guiding
policy decisions and programme design, especially in limited
resource scenarios. Future research in this field should focus on
properly quantifying costs related to increased programme
coverage and scale-up, which are currently difficult to estimate.
Supporting Information
Figure S1 Scenario A: Minimising health service costs
and HCV health utility losses. Simulations are with a 45%
baseline prevalence, showing (A) programme coverage, (B)
prevalence reductions, (C) number of treatments, (D) total health
service costs (comprised of programme costs and infection costs),
(E) infections averted, and (F) net monetary benefit. Parameters
used are as shown in Tables 1–2, with f20~3,800, b20~
5,800|(1=v), tf~50, and with no final time prevalence target
constraint.
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Figure S2 Scenario B: Minimising health service costs
and HCV health utility losses with a final time
prevalence target. Simulations are with a 45% baseline
prevalence, showing (A) programme coverage, (B) prevalence
reductions, (C) number of treatments, (D) total health service costs
(comprised of programme costs and infection costs), (E) infections
averted, and (F) net monetary benefit. Parameters used are as
shown in Tables 1–2, with f20~3,800, b20~5,800|(1=v), and a
final time prevalence target constraint.
(TIFF)
Figure S3 Scenario C: Minimising only health service
costs with a final time prevalence target. Simulations are
with a 45% baseline prevalence, showing (A) programme
coverage, (B) prevalence reductions, (C) number of treatments,
(D) total health service costs (comprised of programme costs and
infection costs), (E) infections averted, and (F) net monetary
benefit. Here, we neglect the health utility losses. Parameters used
are as shown in Tables 1–2, with f20~0, b20~0, and a final time
prevalence target constraint.
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Figure S4 Uncertainty analysis results for optimal
control. Simulations are shown for Scenario A (top) and Scenario
B (bottom). The baseline prevalence is 45%, and maximum yearly
budget is limited to M = »200,000. The cost coefficients b10, b20,
f10, f20 are uniformly distributed with means given in Table 2 and
the ranges given by plus and minus 10% of the means. The range
for c0 is »39,000–53,000. The parameters a1, a2=3, m and d are
uniformly distributed with the ranges given in Table 3.
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